Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.34 USD | +2.57% | -5.25% | -29.36% |
Apr. 09 | UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating | MT |
Apr. 03 | Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing | MT |
- Stock Market
- Equities
- DNLI Stock
- News Denali Therapeutics Inc.